Safety profile of rofecoxib as used in general practice in England: Results of a prescription-event monitoring study

British Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2003, Pages 166-174

  Layton, Deborah ^a   Riley, Jane ^a   Wilton, Lynda V ^a   Shakir, Saad A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Adverse events; COX 2 selective inhibitors; Drug safety; Prescription event monitoring; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; APHASIA; ARTICLE; CEREBROVASCULAR ACCIDENT; COLON PERFORATION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DYSPEPSIA; DYSPHASIA; DYSPNEA; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTICE; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; INSOMNIA; IRON DEFICIENCY ANEMIA; JAUNDICE; KIDNEY FAILURE; LASSITUDE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MELENA; MIGRAINE; NAUSEA; OSTEOARTHRITIS; PANCREATITIS; PATIENT MONITORING; PEPTIC ULCER; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RASH; RECTUM HEMORRHAGE; SEDATION; STEVENS JOHNSON SYNDROME; STOMACH PROTECTION; THROMBOEMBOLISM; TREATMENT INDICATION; UNITED KINGDOM; VERTIGO; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DYSPEPSIA; ENGLAND; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LACTONES; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; SULFONES;

EID: 0037329150     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01763.x     Document Type: Article

References (41)

1. Merck Sharpe Dohme. Summary of Product Characteristics: Vioxx. 1999.
2. McKenna F. COX-2: separating myth from reality. Scand J Rheumatol Suppl 1999; 109: 19-29.
3. Kam PC, See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000; 55: 442-449.
4. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterol 1999, 117: 776-783.
5. Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.
6. Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000; 43: 978-987.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
8. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43: 370-377.
9. Mann RD. Prescription-event monitoring - recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201.
10. Campbell M, Daly L, Machin D. Special topics. In Statistics with Confidence, eds Altman D, Machin D, Bryant T, Gardner MJ. Bristol: BMJ Books, 2000.
11. Legemaate J. The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law 1994; 1: 161-165.
12. Royal College of Physicians of London. Guidelines on the Practice of Ethical Committees in Medical Research Involving Human Subjects. 1996.
13. Multi-Centre Research Ethics Committees Guidance Notes. Examples of Enquiries and Surveys in the Public Interest Where No Reference to a Research Ethics Committee Is Necessary. Appendix C, 2000: 19.
14. Machin D, Campbell M, Fayers P et al. Sample Size Tables for Clinical Studies. Oxford: Blackwell Science, 1997.
15. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1-S29.
16. Strom B. Study designs available for pharmacoepidemiology studies. In Pharmacoepidemiology, Strom B, ed. Chichester: John Wiley & Sons Ltd., 2000: 17-29.
17. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study. BMJ 1998; 317: 119-120.
18. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-1873.
19. Templeton L, Deehan A, Taylor C, Drummond C, Strang J. Surveying general practitioners: does a low response rate matter? Br J General Pract 1997; 47: 91-94.
20. McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ 1996; 313: 732-733.
21. Deehan A, Templeton L, Taylor C, Drummond C, Strang J. The effect of cash and other financial inducements on the response rate of general practitioners in a national postal study. Br J General Pract 1997; 47: 87-90.
22. Key C, Layton D, Shakir SA. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidemiol Drug Saf 2002; 11: 143-148.
23. Wensing M, Mainz J, Kramme O, Jung HP, Ribacke M. Effect of mailed reminders on the response rate in surveys among patients in general practice. J Clin Epidemiol 1999; 52: 585-587.
24. Whitfield M. Giving feedback to questionnaire responders - essential task? Br J General Pract 1997; 47: 241-243.
25. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2998-3003.
26. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
27. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40: 1345-1350.
28. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996; 31: 126-130.
29. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal antiinflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-1337.
30. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796.
31. Raskin JB. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am J Med 1999; 106: 3S-12S.
32. Wilton LV, Stephens MD, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999; 319: 1165-1166.
33. Lipsky PE, Brooks P, Crofford LJ et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160: 913-920.
34. Food and Drug Administration Advisory Committee. Cardiovascular safety review of rofecoxib. http:/http://www.fda.gov/ohrms/dockets/ac/01/briefing/367762_06_cardio.pdf 8-9-2001. 2001.
35. Daniels B, Seidenberg B. Cardiovascular safety profile of rofecoxib in controlled clinical trials. Arthritis Rheum 1999; 42 (Suppl. S143).
36. Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-1120.
37. The physicians' health study: aspirin for the primary prevention of myocardial infarction. N Engl J Med 1988; 318: 924-926.
38. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 1993; 14: 951-957.
39. Boers M. NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222-1223.
40. CSM/MCA. In focus ... Rofecoxib (Vioxx). Current Problems Pharmacovigilance 2000; 26: 13.
41. National Institute of Clinical Excellence. Guidance on Use of Cyclo-Oxygenase (COXII) Selective Inhibitors Celecoxib, Rofecoxib, Meloxicam and Etodoloac for Osteoarthritis and Rheumatoid Arthritis. Technology Appraisal No. 27. London: Department of Health, 2001.